Pancreatic β-Cell Dysfunction and Risk of New-Onset Diabetes After Kidney Transplantation

• Published in: Diabetes care Vol. 36; no. 7; pp. 1926 - 1932
• Main Authors: ZELLE, Dorien M, CORPELEIJN, Eva, DEINUM, Jolijn, STOLK, Ronald P, GANS, Rijk O. B, NAVIS, Gerjan, BAKKER, Stephan J. L
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01-07-2013
• Subjects: Adult; Biological and medical sciences; Diabetes Mellitus - physiopathology; Diabetes Mellitus - surgery; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Fasting - blood; Humans; Insulin-Secreting Cells - physiology; Kaplan-Meier Estimate; Kidney Transplantation; Kidneys; Medical sciences; Metabolic diseases; Middle Aged; Miscellaneous; Original Research; Pancreatic beta cells; Physiological aspects; Proinsulin - blood; Prospective Studies; Public health. Hygiene; Public health. Hygiene-occupational medicine; Risk factors; Transplantation; Type 2 diabetes; Netherlands; Endocrinopathy; Human; Nutrition; Diabetes mellitus; Metabolic diseases; Risk; Early stage; Dysfunction; Surgery; Risk factor; β Cell; Pancreas; Endocrinology; Kidney transplantation
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc12-1894

Chronic exposure to calcineurin inhibitors and corticosteroids poses renal transplant recipients (RTR) at high risk for development of new-onset diabetes after transplantation (NODAT). Pancreatic β-cell dysfunction may be crucial to the pathophysiology of NODAT and specific markers for β-cell dysfunction may have additive value for predicting NODAT in this population. Therefore, we prospectively investigated whether proinsulin, as a marker of pancreatic β-cell dysfunction, is associated with future development of NODAT and improves prediction of it.
All RTR between 2001 and 2003 with a functioning graft for ≥1 year were considered eligible for inclusion, except for subjects with diabetes at baseline who were excluded. We recorded incidence of NODAT until April 2012.
A total of 487 RTR (age 50 ± 12 years, 55% men) participated at a median time of 6.0 (interquartile range [IQR], 2.6-11.5) years after transplantation. Median fasting proinsulin levels were 16.6 (IQR, 11.0-24.2) pmol/L. During median follow-up for 10.1 (IQR, 9.1-10.4) years, 42 (35%) RTR had development of NODAT in the highest quartile of the distribution of proinsulin versus 34 (9%) in the lowest three quartiles (P < 0.001). In Cox regression analyses, proinsulin (hazard ratio, 2.29; 95% CI, 1.85-2.83; P < 0.001) was strongly associated with NODAT development. This was independent of age, sex, calcineurine inhibitors, prednisolone use, components of the metabolic syndrome, or homeostasis model assessment.
In conclusion, fasting proinsulin is strongly associated with NODAT development in RTR. Our results highlight the role of β-cell dysfunction in the pathophysiology of NODAT and indicate the potential value of proinsulin for identification of RTR at increased risk for NODAT.